Inhalation devices for long-acting β2-agonists: Efficiency and ease of use of dry powder formoterol inhalers for use by patients with asthma and COPD

Current Medical Research and Opinion

Volumn 23, Issue 10, 2007, Pages 2405-2413

  Molimard, Mathieu ^a   Till, Denise ^b   Stenglein, Stephan ^c   Singh, Dilraj ^d   Krummen, Markus ^d  

^a HÔPITAL PELLEGRIN   (France)

^b NOVARTIS HORSHAM RESEARCH CENTRE   (United Kingdom)

^c NOVARTIS PHARMA GMBH   (Germany)

^d NOVARTIS PHARMA AG   (Switzerland)

Author keywords

Aerolizer; Asthma; COPD; Dry powder inhaler; Foradil; Formoterol

Indexed keywords

BUDESONIDE; FORMOTEROL; SALBUTAMOL; TERBUTALINE; TIOTROPIUM BROMIDE;

AIRFLOW; ASTHMA; CHRONIC OBSTRUCTIVE LUNG DISEASE; DRUG DELIVERY SYSTEM; DRUG EFFICACY; DRY POWDER; FLOW RATE; HUMAN; IN VITRO STUDY; INHALER; PATIENT COMPLIANCE; REVIEW; SINGLE DRUG DOSE;

ADMINISTRATION, INHALATION; ADRENERGIC BETA-AGONISTS; AIRWAY RESISTANCE; ANTI-ASTHMATIC AGENTS; ASTHMA; BRONCHODILATOR AGENTS; ETHANOLAMINES; HUMANS; METERED DOSE INHALERS; POWDERS; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; RECEPTORS, ADRENERGIC, BETA-2;

EID: 35648945330     PISSN: 03007995     EISSN: None     Source Type: Journal    
DOI: 10.1185/030079907X219698     Document Type: Review

References (77)

1. Roche N, Huchon GJ. Rationale for the choice of an aerosol delivery system. J Aerosol Med 2000;13:393-404
2. British Thoracic Society Nebulizer Project Group. Nebulizer therapy. Guidelines. Thorax 1997;52(Suppl. 2):S4-S24
3. Liard R, Zureik M, Aubier M, et al. Misuse of pressurized metered-dose inhalers by asthmatic patients treated in French private practice. Rev Epidemiol Sante Publique 1995;43: 242-9
4. Roche N, Chinet T, Huchon G. Ambulatory inhalation therapy in obstructive lung diseases. Respiration 1997;64:121-30
5. Breeders ME, Molema J, Hop WC, Folgering HT. Inhalation profiles in asthmatics and COPD patients: reproducibility and effect of instruction. J Aerosol Med 2003;16:131-41
6. Molimard M, Raherison C, Lignot S, et al. Assessment of handling of inhaler devices in real life: an observational study in 3811 patients in primary care. J Aerosol Med 2003;16: 249-54
7. Ross DL, Gabrio BJ. Advances in metered dose inhaler technology with the developments of a CFC-free drug delivery system. J Aerosol Med 1999;12:151-60
8. McDonald KJ, Martin GP. Transition to CFC-free metered dose inhalers - into the new millennium. Int J Pharm 2000;201: 89-107
9. Ashurst I, Malton A, Prime D, Sumby B. Latest advances in the development of dry powder inhalers. Pharm Sci Technol Today 2000;3:246-56
10. Newman SP, Busse WW. Evolution of dry powder inhaler design, formulation, and performance. Respir Med 2002;96:293-304
11. Smith IJ. The challenge of reformulation. J Aerosol Med 1995;8(Suppl. 1):S19-S27
12. Cripps A, Riebe M, Schulze M, Woodhouse R. Pharmaceutical transition to non-CFC pressurized metered dose inhalers. Respir Med 2000;94(Suppl. B):S3-S9
13. Dolovich M. New propellant-free technologies under investigation. J Aerosol Med 1999;12(Suppl. 1):S9-S17
14. Wallin A, Sandstrom T, Rosenhall L, Melander B. Time course and duration of action of bronchodilation with formoterol dry powder in patients with stable astfima. Thorax 1993;48:611-4
15. Dolovich M. Influence of respiratory flow rate, particle size, and airway caliber on aerosolized drug delivery to the lung. Respir Care 2000;45:597-608
16. Clark AR. Medical aerosol inhalers: past, present and future. Aerosol Sci Technol 1995;22:374-91
17. Clark AR, Hollingworth AM. The relationship between powder inhaler resistance and peak inspiratory conditions in healthy volunteers - implications for in vitro testing. J Aerosol Med 1993;6:99-110
18. Timsina M, Martin GP, Marriott C, et al. Studies on the effects of dry powder inhalers upon peak inspiratory flow (PIF) in volunteers. J Aerosol Med 1993;6(Suppl.):1053
19. de Koning JP, van der Mark ThW, Coenegracht PMJ, et al. Effect of an external resistance to airflow on the inspiratory flow curve. Int J Pharm 2002;234:257-66
20. National Asthma Education and Prevention Program. Expert panel report 2: guidelines for the diagnosis and management of asthma. Bethesda (MD): US Dept of Health and Human Services, Public Health Service; 1998 [NIH publication No. 98-4051]
21. Engel T, Heinig JH, Madsen F, Nikander K. Peak inspiratory flow and inspiratory vital capacity of patients with asthma measured with and without a new dry-powder inhaler device (Turbuhaler). Eur Respir J 1990;3:1037-41
22. Pedersen S, Hansen OR, Fuglsang G. Influence of inspiratory flow rate upon the effect of a Turbuhaler. Arch Dis Child 1990;65:308-10
23. Clark AR. Effect of powder inhaler resistance upon inspiratory profiles in health and disease. In: Dalby RN, Byron PR, Farr SJ, editors. Respiratory drug delivery IV. Buffalo Grove: Interpharm Press; 1994. p. 117-24
24. Srichana T, Martin GP, Marriott C. Dry powder inhalers: the influence of device resistance and powder formulation on drug and lactose deposition in vitro. Eur J Pharm Sci 1998;7:73-80
25. Olsson B, Asking L. Critical aspects of the function of inspiratory flow driven inhalers. J Aerosol Med 1994;7(Suppl. 1):S43-S47
26. Chege JK, Chrystyn H. The relative bioavailability of salbutamol to the lung using urinary excretion following inhalation from a novel dry powder inhaler: the effect of inhalation rate and formulation. Respir Med 2000;94:51-6
27. Weuthen T, Roeders S, Brand P, et al. In vitro testing of formoterol dry powder inhalers at different flow rates. J Aerosol Med 2002;15:297-303
28. Novartis Pharma AG, data on file
29. Ganderton D, Byron PR. Harmonising inhaler testing across the pharmacopoeias. In: Dalby RN, Byron PR, Farr SJ, editors. Respiratory drug delivery V. Buffalo Grove: Interpharm Press; 1996. p. 283-92
30. Malton A, Sumby BS, Smith IJ. A comparison of in vitro drug delivery from two multidose powder inhalation devices. Eur J Clin Res 1995;7:177-93
31. Meakin BJ, Dimond P, Lee D. Bricanyl Turbuhaler, Serevent Accuhaler and Foradil Aerolizer: comparative drug delivery. Thorax 1996;51(Suppl. B):A73
32. Bronsky EA, Grossman J, Henis MMJ, et al. Inspiratory flow rates and volumes with the Aerolizer dry power inhaler in asthmatic children and adults. Curr Med Res Opin 2004;20:131-7
33. Krummen M, Singh D, Fiebich K, Haeberlin B. Flow-dependent performance of several formoterol dry powder inhalers (DPIs). Eur Respir J 2006(Suppl.):435s [abstract]
34. 2-agonists administered by a dry powder inhaler can be used in acute asthma. Respir Med 1998;92:167-72
35. 2-agonist particle size. Am J Respir Crit Care Med 2005;172: 1497-504
36. Chew NY, Chan HK. In vitro aerosol performance and dose uniformity between the Foradil Aerolizer and the Oxis Turbuhaler. J Aerosol Med 2001;14:495-501
37. Hindle M, Byron PR. Dose emissions from marketed dry powder inhalers. Int J Pharm 1995;116:169-77
38. FDA. Guidance for industry. Metered dose inhaler (MDI) and dry powder inhaler (DPI) drug products. US Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research (CDER), October 1998. Available at: http://www.fda.gov/cder/guidance/2180dft. pdf [Last accessed 2 October 2006]
39. Criée CP, Meyer T, Petro W, et al. In vitro comparison of two delivery devices for administering formoterol: Foradil® P and formoterol ratiopharm single-dose capsule inhaler. J Aerosol Med 2006;19:466-72
40. Jackson C, Lipworth B. Optimizing inhaled drug delivery in patients with asthma. Br J Gen Pract 1995;45:683-7
41. Lenney J, Innes JA, Crompton GK. Inappropriate inhaler use: assessment of use and patient preference of seven inhalation devices. Respir Med 2000;94:496-500
42. Cochrane MG, Bala MV, Downs KE, et al. Inhaled corticosteroids for asthma therapy: patient compliance, devices, and inhalation technique. Chest 2000;117:542-50
43. Crompton GK. The adult patient's difficulties with inhalers. Lung 1990;168(Suppl.):658-62
44. Giraud V, Roche N. Misuse of corticosteroid metered-dose inhaler is associated with decreased asthma stability. Eur Respir J 2002;19:246-51
45. Clauzel A-M, Molimard M, Le Gros V, et al. Use of formoterol dry powder administered for three months via a single dose inhaler in 1380 asthmatic patients. J Investig Allergol Clin Immunol 1998;8:265-70
46. Girodet PO, Raherison C, Abouelfath A, et al. Real-life use of inhaler devices for chronic obstructive pulmonary disease in primary care. Therapie 2003;58:499-504
47. van der Palen J, Klein JJ, van Herwaarden CL, et al. Multiple inhalers confuse asthma patients. Eur Respir J 1999;14:1034-7
48. Fiocchi A, Terracciano L, Arrigoni S, Bonvini G. Device preference and efficacy of formoterol Aerolizer and salbutamol MDI in children with asthma. Eur Respir J 2003;22(Suppl. 45):134s [abstract P888]
49. Pearlman DS, Kottakis J, Till D, Della Cioppa G. Formoterol delivered via a dry powder inhaler (Aerolizer): results from long-term clinical trials in children. Curr Med Res Opin 2002;18:445-55
50. Melani AS, Zanchetta D, Barbato N, et al. Inhalation technique and variables associated with misuse of conventional metered-dose inhalers and newer dry powder inhalers in experienced adults. Ann Allergy Asthma Immunol 2004;93:439-46
51. Maesen FPV. Long lasting treatment of stable moderately severe asthma patients with formoterol alone does not lead to desensitization. Eur Respir J 1994;7(Suppl. 18):110S
52. Vervloet D, Ekstrom T, Pela R, et al. A 6-month comparison between formoterol and salmeterol in patients with reversible obstructive airways disease. Respir Med 1998;92:836-42
53. FitzGerald JM, Chapman KR, Della Cioppa G, et al. Sustained bronchoprotection, bronchodilatation and symptom control during regular formoterol use in asthma of moderate or greater severity. J Allergy Clin Immunol 1999;103:427-35
54. Bensch G, Berger WE, Blokhin BM, et al. One-year efficacy and safety of inhaled formoterol dry powder in children with persistent asthma. Ann Allergy Asthma Immunol 2002;89:180-90
55. Thomson NC, Angus R, Quebe-Fehling E, Brambilla R. Efficacy and tolerability of formoterol in elderly patients with reversible obstructive airways disease. Respir Med 1998;92:562-7
56. Hacki MA, Hinz GW, Medici TC. Clinical experience over 5 years of daily therapy with formoterol in patients with bronchial asthma. Clin Drug Invest 1997;14:165-74
57. Dahl R, Greefhorst LAPM, Nowak D, et al. Inhaled formoterol dry powder versus ipratropium bromide in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2001;164:778-84
58. Rossi A, Kristufek P, Levine BE, et al. Comparison of the efficacy, tolerability, and safety of formoterol dry powder and oral, slow-release theophylline in the treatment of COPD. Chest 2002;121:1058-69
59. Bensch G, Lapidus RJ, Levine BE, et al. A randomized, 12-week, double-blind, placebo-controlled study comparing formoterol dry powder inhaler with albuterol metered-dose inhaler. Ann Allergy Asthma Immunol 2001;86:19-27
60. Pleskow W, LaForce CF, Yegen U, et al. Formoterol delivered via the dry powder Aerolizer inhaler versus albuterol MDI and placebo in mild-to-moderate asthma: a randomized, double-blind, double-dummy trial. J Asthma 2003;40:505-14
61. Benhamou D, Cuvelier A, Muir JF, et al. Rapid onset of bronchodilation in COPD: a placebo-controlled study comparing formoterol (Foradil Aerolizer) with salbutamol (Ventodisk). Respir Med 2001;95:817-21
62. Richter K, Stenglein S, Mucke M, et al. Onset and duration of action of formoterol and tiotropium in patients with moderate to severe COPD. Respiration 2006;73:414-9
63. Steffensen I, Faurschon P, Riska H, et al. Inhaled formoterol dry powder in the treatment of patients with reversible obstructive airways disease. Allergy 1995;50:657-63
64. 2-agonists: formoterol (Foradil) and salmeterol (Serevent). J Allergy Clin Immunol 1998;101: S186-S187 [abstract]
65. Molimard M, Bourcereau J, Le Gros V, et al. Comparison between formoterol 12 μg b.i.d. and on-demand salbutamol in moderate persistent asthma. Respir Med 2001;95:64-70
66. Lotvall J, Mellen A, Ardvisson P, et al. Similar bronchodilation with formoterol delivered by Aerolizer® or Turbuhaler®. Can Respir J 1999;6:412-6
67. Eliraz A, Ramirez-Rivera A, Ferranti P, et al. Similar efficacy following four weeks treatment of asthmatics with formoterol 12 μg b.i.d. delivered by two different dry powder inhalers; differences in inhaler handling. Int J Clin Pract 2001;55: 164-70
68. Schlimmer P. Single-dose comparison of formoterol (Oxis) Turbuhaler 6 μg and formoterol Aerolizer 12 μg in moderate to severe asthma: a randomised, crossover study. Pulm Pharmacol Ther 2002;15:369-74
69. Otto-Knapp R, Conrad F, Hosch S, et al. Efficacy and safety of formoterol delivered through the Novolizer®, a novel dry powder inhaler (DPI) compared with a standard DPI in patients with moderate to severe asthma. Pulm Pharmacol Ther 2006 December 14; [Epub ahead of print]
70. Dubakiene R, Nargela R, Sakalauskas R, et al. Clinically equivalent bronchodilatation achieved with formoterol delivered via Easyhaler and Aerolizer. Respiration 2006;73:441-8
71. Randell J, Saarinen A, Walamies M, et al. Safety of formoterol after cumulative dosing via Easyhaler and Aerolizer. Respir Med 2005;99:1485-93
72. Houghton CM, Langley SJ, Singh SD, et al. Comparison of bronchoprotective and bronchodilator effects of a single dose of formoterol delivered by hydrofluoroalkane and chlorofluorocarbon aerosols and dry powder in a double blind, placebo-controlled, crossover study. Br J Clin Pharmacol 2004;58:359-66
73. Bousquet J, Huchon G, Leclerc V, et al. A randomized, double-blind, double-dummy, single-dose, efficacy crossover trial comparing formoterol-HFA (pMDI) versus formoterol-DPI (Aerolizer) and placebo (pMDI or Aerolizer) in asthmatic patients. Respiration 2005;72(Suppl 1):6-12
74. Bousquet J, Guenole E, Duvauchelle T, et al. A randomized, double-blind, double-dummy, single-dose, crossover trial evaluating the efficacy and safety profiles of two dose levels (12 and 24 μg) of formoterol-HFA (pMDI) vs. those of a dose level (24 μg) of formoterol-DPI (Foradil/Aerolizer) and of placebo (pMDI or Aerolizer) in moderate to severe asthmatic patients. Respiration 2005;72(Suppl 1):13-9
75. Lipworth BJ, Sims EJ, Das SK, et al. Bronchoprotection with formoterol via dry powder and metered-dose inhalers in patients with asthma. Ann Allergy Asthma Immunol 2005;95:283-90
76. Dahl R, Creemers JP, Van Noord J, et al. Comparable efficacy and tolerability of formoterol (Foradil) administered via a novel multi-dose dry powder inhaler (Certihaler) or the Aerolizer dry powder inhaler in patients with persistent asthma. Respiration 2004;71:126-33
77. Chuchalin AG, Manjra AI, Rozinova NN, et al. Formoterol delivered via a new multi-dose dry powder inhaler (Certihaler) is as effective and well tolerated as the formoterol dry powder inhaler (Aerolizer) in children with persistent asthma. J Aerosol Med 2005;18:63-73